Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FER | P16591 | 1/20 | 0.35 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201031 | 1.00 | DPP4 (0.41) | DPP4KAT2BCHRM1SYKCHEK1 | |
| SCHEMBL4065711 | 1.00 | DPP4 (0.41) | DPP4KAT2BCHRM1SYKCHEK1 | |
| Trifluoroacetic Acid SCHEMBL2965093 | 0.92 | IRAK4 (0.40) | DPP4CHRM1SYK | |
| Trifluoroacetic Acid SCHEMBL2952356 | 0.92 | IRAK4 (0.40) | DPP4CHRM1SYK | |
| SCHEMBL13969617 | 0.87 | KAT2B (0.42) | DPP4KAT2BSYKCHEK1PAK4 | |
| SCHEMBL13217465 | 0.87 | KAT2B (0.42) | DPP4KAT2BSYKCHEK1PAK4 | |
| SCHEMBL2954861 | 0.72 | DPP4 (0.68) | DPP4CHRM1 | |
| SCHEMBL8286495 | 0.72 | DPP4 (0.51) | DPP4CHRM1 | |
| SCHEMBL2962657 | 0.71 | DPP4 (0.37) | DPP4KAT2BCHRM1 | |
| SCHEMBL4250824 | 0.70 | DPP4 (0.54) | DPP4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | DPP4 1/4885KAT2B 1271/4885CHRM1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.